Skip to Content
UW Health SMPH
American Family Children's Hospital
E. Jason Abel, MD close
BiumugHiAAA
E. Jason Abel, MD
 

Learn More

Six Lauded With UW Health Physician Excellence Awards

UW Health Urologist Motivated by Progress, Opportunity

Find a Doctor Quick Search

Find a Doctor Home

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

E. Jason Abel, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Abel is board certified by the American Board of Urology and specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers, including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

 

Dr. Abel performs open and laparoscopic surgery, including surgery using the daVinci robot. His philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Specialties

Urology

UW Health Clinics

UW Hospital and Clinics
(608) 263-4757 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)
Meriter Hospital (secondary)

Languages Spoken

English
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship

Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX
Residency University of Utah, Salt Lake City
Internship University of Utah, Salt Lake City
Medical School University of Texas, Houston Medical School, Houston, TX, 2003

Procedures

Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

Research

Dr. Abel conducts clinical, translational and basic research in urologic oncology. He currently is involved in several projects focusing on the development and metastasis of kidney cancer.

PubMed Articles
Truong M Slezak JA Lin CP Iremashvili V Sado M Razmaria AA Leverson G Soloway MS Eggener SE Abel EJ Downs TM Jarrard DF . Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15;119(22):3992-4002
[PubMed ID: 24006289]
Abel EJ Thompson RH Margulis V Heckman JE Merril MM Darwish OM Krabbe LM Boorjian SA Leibovich BC Wood CG . Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. Eur Urol. 2013 Nov 7;
[PubMed ID: 24262104]
Abel EJ Fisher MB Matin SF Kamat AM Dinney CP Grossman HB . Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol. 2013 Nov-Dec;39(6):817-22
[PubMed ID: 24456786]
Abel EJ Carrasco A Karam J Tamboli P Delacroix S Vaporciyan AA Wood CG . Positive vascular wall margins have minimal impact on cancer outcomes in non-metastatic RCC patients with tumor thrombus. BJU Int. 2013 Oct 15;
[PubMed ID: 24128265]
Abel EJ Wood CG Eickstaedt N Fang JE Kenney P Bagrodia A Youssef RF Sagalowsky AI Margulis V . Preoperative pulmonary embolism does not predict poor postoperative outcomes in patients with renal cell carcinoma and venous thrombus. J Urol. 2013 Aug;190(2):452-7
[PubMed ID: 23434945]
Margulis V Shariat SF Rapoport Y Rink M Sjoberg DD Tannir NM Abel EJ Culp SH Tamboli P Wood CG . Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013 May;63(5):947-52
[PubMed ID: 23273681]
Patel SR Abel EJ Hedican SP Nakada SY . Ablation of small renal masses: practice patterns at academic institutions in the United States. J Endourol. 2013 Feb;27(2):158-61
[PubMed ID: 22974005]
Abel EJ Carrasco A Culp SH Matin SF Tamboli P Tannir NM Wood CG . Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. 2012 Dec;110(11):1742-6
[PubMed ID: 22503066]
Masterson TA Carver BS Abel EJ Pettus JA Bosl GJ Sheinfeld J . Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. BJU Int. 2012 Oct;110(7):950-5
[PubMed ID: 22394608]
Abel EJ Culp SH Tannir NM Tamboli P Matin SF Wood CG . Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011 Dec;60(6):1273-9
[PubMed ID: 21784574]
Abel EJ Karam JA Carrasco A Matin SF . Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol. 2011 Aug;25(8):1323-7
[PubMed ID: 21774667]
Cost NG Delacroix SE Jr Sleeper JP Smith PJ Youssef RF Chapin BF Karam JA Culp S Abel EJ Brugarolas J Raj GV Sagalowsky AI Wood CG Margulis V . The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun;59(6):912-8
[PubMed ID: 21367518]
Karam JA Zhang XY Tamboli P Margulis V Wang H Abel EJ Culp SH Wood CG . Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol. 2011 Apr;59(4):619-28
[PubMed ID: 21167632]
Abel EJ Culp SH Tannir NM Matin SF Tamboli P Jonasch E Wood CG . Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan;59(1):10-5
[PubMed ID: 20952123]
Abel EJ Culp SH Meissner M Matin SF Tamboli P Wood CG . Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU Int. 2010 Nov;106(9):1277-83
[PubMed ID: 20394619]
Abel EJ Culp SH Matin SF Tamboli P Wallace MJ Jonasch E Tannir NM Wood CG . Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov;184(5):1877-81
[PubMed ID: 20850148]
Culp SH Tannir NM Abel EJ Margulis V Tamboli P Matin SF Wood CG . Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010 Jul 15;116(14):3378-88
[PubMed ID: 20564061]
Bennett SD Foot LM Abel EJ Snow BW Cartwright PC Devries CR Wallis MC . Is there a learning curve for subureteric injection of dextranomer/hyaluronic acid in the treatment of vesicoureteral reflux? J Pediatr Urol. 2010 Apr;6(2):122-4
[PubMed ID: 19740702]
Abel EJ Wood CG . Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009 Jul;6(7):375-83
[PubMed ID: 19528960]
Abel EJ Masterson TA Warner JN Valentine K Dechet C . Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology. 2009 Jun;73(6):1336-40
[PubMed ID: 19362347]